NCT06613230Completed
Improved Early Diagnosis in Female Pelvic Cancer With OC Detect
Improved Early Diagnosis and Survival in Female Pelvic Cancer (e.g. Ovarian Cancer) With OC Detect, (Pilot Study)
Source: ClinicalTrials.gov · Last updated 18 Apr 2025
Brief summary (registry, in English)
The goal of this observational study is to learn if so called Volatile Organic Compounds (VOCs) in blood can be used for early diagnosis of ovarian cancer. The main question it aims to answer is: Can OC Detect, a new in vitro diagnostic instrument, distinguish between VOC patterns in blood plasma from women with ovarian cancer (especially in early stage) and VOC patterns in helthy women? Participants are previosuly diagnosed patients with ovarian cancer, who agreed to store their blood samples in biobanks for future medical research purposes. Healthy female blood donors serve as benign control blood samples.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 490 (actual)
- First submitted
- 26 Aug 2024
- Start date
- 1 Feb 2024
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Region Skane
- Diseases
- Melanoma, Endometrial cancer, Ovarian cancer, Sarcoma
- NCT number
- NCT06613230
What you commit to
- Study type: Observational
- Participants enrolled: 490
- From 1 Feb 2024 to the primary completion date, 31 Dec 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- \< 18 years (both for cancer patients and healthy blood donors)
- \>70 years (healthy blood donors)
Other
- Man (healthy blood donors)
Who the study is looking for
- Blood plasma (1ml) from patients with ovarian cancer or borderline ovarian tumors, or other cancer tumors (endometrial, lymphoma, breast, malignant melanoma, sarcoma)
- Blood plasma (1 ml) from healthy volunteer controls
- Signed informed consent by cancer patients for use of biobank blood samples in research
- Signed informed consent by healthy blood donors for use in research
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Linköping University Coordinator of this site? Confirm its status | Linköping | Sweden | Unknown status |
| Region Skane Coordinator of this site? Confirm its status | Lund | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.